Tim J von Oertzen (Kepler Universitätsklinikum, Linz, Austria) describes interim findings that highlight the promising utility of multiple subtraction ictal SPECT coregistered to MRI (SISCOM) to guide presurgical evaluation of patients with drug-refractory epilepsy.
1. What are the major challenges in the presurgical evaluation of candidates with drug-refractory epilepsy? (0:05)
2. Could you give us a brief overview of SISCOM and its utility in demonstrating blood flow changes during seizures? (0:48)
3. Could you tell us a little about the rationale and aims of your study investigating hyperperfusion zones in multiple SISCOMs and the correlation with surgical site and post-surgical outcomes? (3:02)
4. What were the outcomes of this study? (4:36)
5. What have we learned from these findings and what future studies are planned? (5:57)
Speaker disclosure: Tim J von Oertzen has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Epilepsy
Pat Penovich, AES 2020 – The Patient Experience With Diazepam Nasal Spray
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
Martin Brodie, CONy 2020 – Combination Antiepileptic Drug Therapy
It was a pleasure to speak with Martin Brodie (President, International Bureau for Epilepsy and co-Section Head of Epilepsy for CONy), who spoke with us on the topic of the debate session he participated in: Should combination antiepileptic drug (AED) therapy be offered immediately after failure of a single antiepileptic drug? Questions Could you tell […]
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!